Trial · NCT00530218

Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant

NCT00530218, Phase 2, Completed, City of Hope Medical Center; results first posted 2017-12-02

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant. Trials, record NCT00530218. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00530218

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant
NCT number: NCT00530218
Status: Completed
Phases: Phase 2
Enrollment: 61 participants, actual
Lead sponsor: City of Hope Medical Center
Conditions: Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Leukemia, Lymphoma, Multiple Myeloma, MDS, Myelodysplastic/Myeloproliferative Diseases
Interventions: Ganciclovir
First posted: 2007-09-17
Last updated: 2017-12-02
Results first posted: 2017-12-02

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Participants With Adverse Events	From first ganciclovir positive test, after day 21 post-hematopoietic cell transplant	This will be measured by the number of the CMV+ participants with adverse events occurring when receiving oral GCV.
Primary	Observation of Cytomegalovirus (CMV) in Blood as Measured by Either Blood Culture or Polymerase Chain Reaction (PCR) During the Course of Antiviral Treatment	Twice Weekly after day 21 post-transplant
Primary	Compliance Rate Among Patients With CMV Reactivation	From first ganciclovir positive test to the end of the 6th week GCV therapy	CMV reactivation patients completed 6-week GCV therapy.

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Participants With Adverse Events	From first ganciclovir positive test, after day 21 post-hematopoietic cell transplant	Patients are treated with Intravenous Ganciclovir followed by Oral Ganciclovir on detection of CMV reactivation. Among the 36 patients with CMV reactivation, four patients' adverse event data are not available.	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Observation of Cytomegalovirus (CMV) in Blood as Measured by Either Blood Culture or Polymerase Chain Reaction (PCR) During the Course of Antiviral Treatment	Twice Weekly after day 21 post-transplant		Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Compliance Rate Among Patients With CMV Reactivation	From first ganciclovir positive test to the end of the 6th week GCV therapy	Among the 36 patients with CMV reactivation, two patients are in-evaluable for compliance.	participants	NUMBER

Source ClinicalTrials.gov

Results by group117

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Number of Participants With Adverse Events	CMV Reactivation Patients With GCV	Haptoglobin	1	Participants
Number of Participants With Adverse Events	CMV Reactivation Patients With GCV	Hemoglobin	31	Participants
Number of Participants With Adverse Events	CMV Reactivation Patients With GCV	Hemolysis	1	Participants
Number of Participants With Adverse Events	CMV Reactivation Patients With GCV	Leukocytes	22	Participants
Number of Participants With Adverse Events	CMV Reactivation Patients With GCV	Lymphopenia	2	Participants
Number of Participants With Adverse Events	CMV Reactivation Patients With GCV	Neutrophils/granulocytes	12	Participants
Number of Participants With Adverse Events	CMV Reactivation Patients With GCV	Platelets	26	Participants
Number of Participants With Adverse Events	CMV Reactivation Patients With GCV	pRBCs	17	Participants
Number of Participants With Adverse Events	CMV Reactivation Patients With GCV	aGVHD	21	Participants
Number of Participants With Adverse Events	CMV Reactivation Patients With GCV	cGVHD	1	Participants

1 to 10 of 117Source ClinicalTrials.gov

See all 117 results by group

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	All Study Participants	61
Overall Study	COMPLETED	All Study Participants	36
Overall Study	NOT COMPLETED	All Study Participants	25

Source ClinicalTrials.gov

Adverse events226

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Haptoglobin	Blood and lymphatic system disorders	Patients With CMV Reactivation Detected	1	32	1
other	Haptoglobin	Blood and lymphatic system disorders	Patients Without CMV Reactivation Detected	0	0	0
other	Hemoglobin	Blood and lymphatic system disorders	Patients With CMV Reactivation Detected	31	32	31
other	Hemoglobin	Blood and lymphatic system disorders	Patients Without CMV Reactivation Detected	0	0	0
other	Hemolysis	Blood and lymphatic system disorders	Patients With CMV Reactivation Detected	1	32	1
other	Hemolysis	Blood and lymphatic system disorders	Patients Without CMV Reactivation Detected	0	0	0
other	Leukocytes	Blood and lymphatic system disorders	Patients With CMV Reactivation Detected	22	32	22
other	Leukocytes	Blood and lymphatic system disorders	Patients Without CMV Reactivation Detected	0	0	0
other	Lymphopenia	Blood and lymphatic system disorders	Patients With CMV Reactivation Detected	2	32	2
other	Lymphopenia	Blood and lymphatic system disorders	Patients Without CMV Reactivation Detected	0	0	0

1 to 10 of 226Source ClinicalTrials.gov

See all 226 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Patients With CMV Reactivation Detected	19	36
Total, all-cause mortality	Patients Without CMV Reactivation Detected	14	25
Total, other adverse events	Patients With CMV Reactivation Detected	32	32
Total, other adverse events	Patients Without CMV Reactivation Detected	0	0
Total, serious adverse events	Patients With CMV Reactivation Detected	0	32
Total, serious adverse events	Patients Without CMV Reactivation Detected	0	0

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
P30CA033572	Cancer Center Support Grant	CARPTEN, JOHN D.	BECKMAN RESEARCH INSTITUTE/CITY OF HOPE	NATIONAL CANCER INSTITUTE	1985 to 2025

Source NIH RePORTER

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Patients With CMV Reactivation Detected vs Patients Without CMV Reactivation Detected: deaths from any cause

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00530218

GET https://conductscience.org/api/trials/v1/NCT00530218/results?page=2

API reference For AI assistants